Ennov, a Paris-based provider of regulatory, quality, and clinical software for life sciences and healthcare companies, has announced a strategic growth investment led by Bregal Sagemount, with participation from Ardian.
The company did not disclose the size or structure of the deal. Ennov said the funding will be used to support continued expansion, with a focus on AI innovation, global go-to-market acceleration, and scaling its product offering.
Founded in France, Ennov develops a unified compliance platform used by life sciences organizations to manage regulatory, quality, commercial, clinical, and pharmacovigilance workflows. The company says its software serves as a centralized system of record for customers operating across complex global regulatory environments.
The transaction is expected to close in late Q2 2026, subject to regulatory approvals and customary closing conditions.
The company did not disclose the size or structure of the deal. Ennov said the funding will be used to support continued expansion, with a focus on AI innovation, global go-to-market acceleration, and scaling its product offering.
Founded in France, Ennov develops a unified compliance platform used by life sciences organizations to manage regulatory, quality, commercial, clinical, and pharmacovigilance workflows. The company says its software serves as a centralized system of record for customers operating across complex global regulatory environments.
The transaction is expected to close in late Q2 2026, subject to regulatory approvals and customary closing conditions.